BB Biotech AG is one of the largest specialized Biotech investment compaies globally, with a track record of over 30 years and currently around $3bn invested Capital. The investment company focuses purely on therapeutic biotech equity with a long-term long-only strategy in mainly public investments but also later-stage private or cross-overs financings. The portfolio is built and managed by a team of seven portfolio managers and three data scientists with different medical and scientific expertise. The board of directors includes former and current Biopharmaceutical industry leaders: Clive Meanwell - Former CEO The Medicines Company, Mads Thomsen - CEO Novo Foundation, Pearl Huang - CEO of Dunad Therapeutics, Laura Hamill - Ex EVP Commercial Gilead, Camilla Soenderby - Ex Takeda/Shire Executive and Chairman Thomas von Planta - Former Goldman Sachs & Vontobel Investment Banker. BB Biotech is listed on the Swiss (BION SW) and German (BBZA GY) with offices in Switzerland, New York and London.Chris' areas of experties and responsibilities are:1) Targeted Oncology- AI/Machine learning assisted drug discovery & development- Structural Biology and Computational Chemistry2) Genetic Medicines- mRNA- Genome editing3) Cardiometabolic Diseases- Cardiomyopathies- Metabolic Syndrome- Lipidology

Bank am Bellevue is a local brokerage firm focusing on Swiss Equity. The Küsnacht based company is part of the Bellevue Group AG that is listed on the SIX Swiss Exchange (BBN SW).

PhD project in bio/chemoinformatics focusing on Machine-Learning algorithms for antigen predictionComputer-assisted drug design in the Department of Chemistry and Applied Biosciences (D-CHAB), Institute of Pharmaceutical Sciences (IPW), Computer-Assisted Drug Design Group of Prof. Gisbert Schneider